Lung cancer screening feasibility in Australia

European Respiratory Journal

Volumn 45, Issue 6, 2015, Pages 1734-1737

  Marshall, Henry M ^a,b   Bowman, Rayleen V ^a,b   Ayres, John ^a   Crossin, Jane ^a   Lau, Melanie ^a   Slaughter, Richard E ^a,c   Redmond, Stanley ^a   Passmore, Linda ^a   McCaul, Elizabeth ^a   Courtney, Deborah ^a   Leong, Steven C ^a,b   Windsor, Morgan ^a,b   Zimmerman, Paul V ^a,b   Yang, Ian A ^a,b   Fong, Kwun M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS;

AGE; AUSTRALIA; BRONCHOSCOPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENVIRONMENTAL EXPOSURE; FALSE POSITIVE RESULT; FINE NEEDLE ASPIRATION BIOPSY; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG ADENOCARCINOMA; LUNG CANCER; NON SMALL CELL LUNG CANCER; POPULATION EXPOSURE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMALL CELL LUNG CANCER; SMOKING; SQUAMOUS CELL LUNG CARCINOMA; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EARLY DIAGNOSIS; FEASIBILITY STUDY; FEMALE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; PROCEDURES; RADIOGRAPHY;

ADENOCARCINOMA; AGE FACTORS; AGED; AUSTRALIA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930398630     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00208714     Document Type: Letter

References (16)

1. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
2. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160: 311-320.
3. Woolf SH, Harris RP, Campos-Outcalt D. Low-dose computed tomography screening for lung cancer: How strong is the evidence? JAMA Intern Med 2014; 174: 2019-2022.
4. Hew M, Stirling RG, Abramson MJ. Should we screen for lung cancer in Australia? Med J Aust 2013; 199: 82-83.
5. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer computed tomography screening workshop 2011 report. J Thorac Oncol 2012; 7: 10-19.
6. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the national lung screening trial. N Engl J Med 2014; 371: 1793-1802.
7. Marshall HM, Bowman RV, Crossin J, et al. Queensland lung cancer screening study: rationale, design and methods. Int Med J 2013; 43: 174-182.
8. National Lung Screening Trial Research Team. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst 2010; 102: 1771-1779.
9. Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007; 369: 844-849.
10. Park EK, Yates DH, Hyland RA, et al. Asbestos exposure during home renovation in New South Wales. Med J Aust 2013; 199: 410-413.
11. Queensland Government. Asbestos investigation - former plants. www.health.qld.gov.au/asbestos Date last accessed: February, 2015. Date last updated: February 19, 2015.
12. The National Lung Screening Trial Research Team. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013; 368: 1980-1991.
13. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013; 369: 920-931.
14. Horeweg N, van der Aalst CM, Vliegenthart R, et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 2013; 42: 1659-1667.
15. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr Date last accessed: May, 2014.
16. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013; 368: 728-736.